Thermo Fisher Scientific Inc
$
270.75
1.2 (0.45%)
| Volume: | 612,982 | Avg Vol (1m): | 1,652,846 |
| Market Cap $: | 108.23 Bil | Enterprise Value $: | 125.12 Bil |
| P/E (TTM): | 37.32 | P/B: | 3.96 |
| Earnings Power Value | 56.76 |
| Net Current Asset Value | -44.76 |
| Tangible Book | -31.64 |
| Projected FCF | 150.51 |
| Median P/S Value | 167.98 |
| Graham Number | 0 |
| Peter Lynch Value | 87.15 |
| DCF (FCF Based) | 169.46 |
| DCF (Earnings Based) | 132.66 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 5/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.11 | ||
| Equity-to-Asset | 0.49 | ||
| Debt-to-Equity | 0.69 | ||
| Debt-to-EBITDA | 3.07 | ||
| Interest Coverage | 5.75 | ||
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 3.48 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.52 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 7.67%
WACC 9.22%
| ||
Profitability & Growth : 8/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 15.74 | ||
| Net Margin % | 12.06 | ||
| ROE % | 11.09 | ||
| ROA % | 5.25 | ||
| ROC (Joel Greenblatt) % | 51.63 | ||
| 3-Year Total Revenue Growth Rate | 12.80 | ||
| 3-Year Total EBITDA Growth Rate | 15.30 | ||
| 3-Year EPS w/o NRI Growth Rate | 13.70 |
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:TMO
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Diagnostics & Research » Diagnostics & Research   NAICS : 541380   SIC : 3826 |
| Compare | NYSE:DHR XAMS:PHIA NYSE:A NYSE:IQV TSE:6869 XSWX:LONN NYSE:LH NAS:IDXX NYSE:DGX XTER:SRT3 SZSE:300676 XPAR:BIM XPAR:ERF NYSE:PKI NYSE:BIO NYSE:QGEN NAS:DXCM NAS:ICLR NAS:EXAS XTER:AFX |
| Traded in other countries | TMOS34.Brazil TN8.Germany TFS.Switzerland 0R0H.UK |
| Address | 168 Third Avenue, Waltham, MA, USA, 02451 |
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments: analytical technologies (about 22% of sales after the FEI acquisition); specialty diagnostic products (16%); life science solutions (26% including Affymetrix); and lab products and services (36% including Patheon and excluding cross-segment sales). | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 37.32 | ||
| Forward PE Ratio | 22.12 | N/A | |
| PE Ratio without NRI | 37.32 | ||
| Price-to-Owner-Earnings | 28.15 | ||
| PB Ratio | 3.96 | ||
| PS Ratio | 4.51 | ||
| Price-to-Free-Cash-Flow | 29.03 | ||
| Price-to-Operating-Cash-Flow | 24.19 | ||
| EV-to-EBIT | 31.84 | ||
| EV-to-EBITDA | 20.20 | ||
| EV-to-Revenue | 5.14 | ||
| PEG Ratio | 2.74 | ||
| Shiller PE Ratio | 60.39 | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.24 | ||
| Days Inventory | 79.56 | ||
| Days Sales Outstanding | 61.98 | ||
| Days Payable | 43.66 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 0.26 | ||
| Dividend Payout Ratio | 0.09 | ||
| 3-Year Dividend Growth Rate (Per Share) | 4.30 | ||
| Forward Dividend Yield % | 0.28 | N/A | |
| Yield-on-Cost (5-Year) % | 0.30 | ||
| 3-Year Share Buyback Rate | -0.20 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 1.80 | ||
| Price-to-DCF (Earnings Based) | 2.04 | ||
| Price-to-Median-PS-Value | 1.61 | ||
| Price-to-Peter-Lynch-Fair-Value | 3.11 | ||
| Earnings Yield (Joel Greenblatt) % | 3.14 | ||
| Forward Rate of Return (Yacktman) % | 14.70 |
More Statistics
| Revenue (TTM) (Mil) $ | 24,358 |
| EPS (TTM) $ | 7.25 |
| Beta | 1.3 |
| Volatility % | 21.8 |
| 52-Week Range $ | 202.83 - 282.98 |
| Shares Outstanding (Mil) | 399.97 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |